Even with new competition, Botox can hold its own in growing migraine field: Allergan executives

Amgen, Teva and Eli Lilly may be racing to scoop up market share in the new CGRP field, but Allergan executives say they're not worried the new class will hurt their market share for Botox, which is used to help patients who suffer from chronic migraines.